| Project/Area Number |
16590833
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
KURODA Yasuo Saga University, Faculty of Medicine, Professor, 医学部, 教授 (30117105)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUEOKA Eisaburo Saga University, Faculty of Medicine, Associate Professor, 医学部, 助教授 (00270603)
SUEOKA Naoko Saga University, Faculty of Medicine, Lecturer, 医学部, 講師 (20321846)
YUKITAKE Motohiro Saga University, Faculty of Medicine, Lecturer, 医学部, 講師 (10304891)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2004: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | multiple sclerosis / ribonucleoproteins / hnRNP B1 / HTLV-I-associated myelopathy / autoimmune disease / cerebrospinal fluid / hnRNP A1 / 自己抗体 / 抗hnRNP抗体 / 疾患マーカー / 多発性硬化 / 自己免疫性中枢神経疾患 / 疾患特異的マーカー / 髄液 / 抗hnRNP-A2抗体 |
|---|
| Research Abstract |
In order to clarify the pathognomic value of antibodies (Abs) against heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 in multiple sclerosis (MS), we assayed anti-hnRNP A1 and A2/B1 Abs in 168 cerebrospinal fluid (CSF) samples in fully masked condition. We used recombinant hn RNP A1 and B1 proteins and Western Immunoblots for the assay. The decoding of CSF samples showed that all were obtained from patients with neurological symptoms tested for the infection with human T-lymphotropic virus type I (HTLV-I). Among the 102 cases with negative anti-HTLV-I Abs, the incidence of CSF anti-hnRNP A2/B1 Abs was the highest in MS group (88.0%, n=25), that was significantly different from the incidence in the group of neurodegenerative diseases (15.5%, n=20) (p<0.0001, that of meningoencephalitis (38.1%, n=21)(p=0.0013) and that of inflammatory polyneuropathies (36.8%, n=19)(p=0.0013). Among the 66 cases with positive anti-HTLV-I Abs, the incidence of CSF anti-hnRNP A1 Abs were far lower in HTLV-!-associated myelopathy (HAM)(35.0%, n=40) than in the group of other neurological diseases (57.7%, n=26). The present study confirmed our previous finding showing CSF anti-hnRNP A2/B1 Abs to become a biomarker in the diagnosis of MS, but it did not support the association between anti-hnRNP A1 and HAM.
|
